1099656-48-0 Usage
Uses
Used in Pharmaceutical Industry:
C6H8F2O is used as a key intermediate in the synthesis of various pharmaceuticals for its unique properties and reactivity, contributing to the development of new drugs with improved therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, C6H8F2O is employed as a precursor in the production of agrochemicals, such as pesticides and herbicides, enhancing their effectiveness and selectivity in controlling pests and weeds.
Used in Polymer Production:
C6H8F2O is used as a building block in the synthesis of polymers, imparting specific characteristics like thermal stability, chemical resistance, and other desirable properties to the resulting polymers.
Used in Chemical Reactions:
As a reagent, C6H8F2O is utilized in a variety of chemical reactions, facilitating the formation of desired products and improving the efficiency of the reaction processes.
Safety Precautions:
Due to its toxic and harmful nature, C6H8F2O requires careful handling to prevent ingestion, inhalation, or skin contact. Proper storage and disposal methods should be followed in accordance with local regulations to minimize environmental and health risks.
Check Digit Verification of cas no
The CAS Registry Mumber 1099656-48-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,9,6,5 and 6 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1099656-48:
(9*1)+(8*0)+(7*9)+(6*9)+(5*6)+(4*5)+(3*6)+(2*4)+(1*8)=210
210 % 10 = 0
So 1099656-48-0 is a valid CAS Registry Number.
1099656-48-0Relevant academic research and scientific papers
HEPATITIS C VIRUS INHIBITORS
-
, (2014/05/24)
The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
HEPATITIS C VIRUS INHIBITORS
-
, (2012/03/09)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment o
HEPATITIS C VIRUS INHIBITORS
-
, (2012/12/13)
The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection of following Fomula (I). Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
